drug
setmelanotide
Marketedupdated 6mo agoby $RYTM RHYTHM PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Protein drug with a maximum clinical stage of Approval, with an approval for obesity.
indications
investigational
Obesity
all catalysts(6)
approval · 6
Nov 25, 2020
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Jun 16, 2022
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Nov 15, 2023
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Dec 20, 2024
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Aug 21, 2025
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Mar 19, 2026
approval
$RYTM116.61+8.49%
IMCIVREE (SETMELANOTIDE ACETATE) — FDA approval
setmelanotide
→
Trials studying setmelanotide
- phase3A Trial of Setmelanotide in Acquired Hypothalamic Obesity
- phase3Open-Label Extension Study of Setmelanotide
- phase2A Study of Setmelanotide in Patients With Prader-Willi Syndrome
- phase3A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
- phase3EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
- phase2DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
- phase3Long Term Extension Trial of Setmelanotide
- phase2Open-Label Study of Setmelanotide in Hypothalamic Obesity
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 13, 2027
329 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Jul 4, 2034formulationUS 11129869
- Aug 21, 2032compositionUS 8039435
- Oct 13, 2027compositionUS 9458195329d
FDA exclusivities (5)
- Dec 20, 2031ODE-508Orphan Drug (7y)
- Dec 20, 2031ODE-509Orphan Drug (7y)
- Jun 16, 2029ODE-402Orphan Drug (7y)2.6y
- Dec 20, 2027NPPNew Product (3y)1.1y
- Nov 25, 2027ODE-336Orphan Drug (7y)1.0y
News(7)
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 4d ago
- Argenx to buy peptide platform in potentially billion-dollar dealFor $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.biopharma_dive · 8d ago
- Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZenecaAstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.biospace · 12d ago
- Rhythm doubles down on LG obesity license, raising payout to as much as $855MRhythm Pharmaceuticals and LG Chem have rewritten the terms of their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, growing to $855 million in scheduled payments from th…fiercebiotech · 15d ago
- Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechNovo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.fiercebiotech · 2mo ago
- An AI drug specialist zeroes in on rare forms of obesitySuperluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…biopharma_dive · 2mo ago
- Chutes & Ladders—Vivace revs up C-suite ahead of pivotal pushVivace Therapeutics has named Craig Gibbs, Ph.D., as its new president and CEO.fiercebiotech · 2mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that